1-888-578-4754 • 24/7 1-888-578-4754 • 24/7 GET FREE ADVICE
The call is free. The advice is free.
Looking for Answers?

Have you been diagnosed with pancreatic cancer or thyroid cancer?

Have you lost a loved one to these cancers?

Could diabetes drugs be to blame? Contact us to find out the deadline for filing a claim in the United States.

Free Case Review
  • This field is for validation purposes and should be left unchanged.

You pay us nothing unless we win your case.

  • You Have Questions
  • We Have Answers
  • We Get Results

Diabetes Drug Makers Ask MDL Judge To Throw Out Insufficient-Warning Claims

Written by on August 31, 2015

Januvia, Janumet, Byetta and Victoza, prescribed to diabetics to help regulate their blood sugar levels, are being blamed for thousands of cases of pancreatic cancer. The manufacturers are already facing more than 700 diabetes drug cancer lawsuit claims from injured patients. Many more are expected to be filed this year. Due to their growing number, the cases have been organized in a multidistrict litigation (MDL) under Judge Anthony Battaglia in California.

Number of Pancreatic Cancer and Diabetes Drug Lawsuits Continues To Grow As Study Investigates Risk

Written by on May 26, 2015

The Milwaukee-Wisconsin Journal Sentinel recently investigated the number of deaths and hospitalizations linked to a small number of diabetes drugs that occurred between 2004 and 2014. Researchers found that Januvia (sitagliptin) was responsible for 964 deaths and 4,425 hospitalizations. Byetta (exenatide) was blamed for 880 deaths and 7,115 hospitalizations. Victoza (liraglutide) is believed to have caused 319 deaths and 2,827 hospitalizations.

Months-Long Investigation of Diabetes Drug FDA Approval Process Offers Several Startling Insights

Written by on May 12, 2015

MedPage Today and the Milwaukee Journal Sentinel joined forces to investigate how diabetes drugs, such as Januvia and Byetta, gain FDA approval. The researchers uncovered multiple studies demonstrating a potentially causal link between diabetes drugs like Januvia and an increased risk of pancreatic cancer. Among those that discovered the possible connection, the majority may underestimate the number of hospitalizations and deaths attributed to such medications.

Januvia Pancreatic Cancer Lawsuit 2016: Doctors And Patients Remain Concerned About Januvia Cancer Side Effects

Written by on April 17, 2015

Januvia, which was approved by the Food and Drug Administration in 2006 and is manufactured by Merck & Co., generates sales in excess of $4 billion each year. It has also spurred growing fears about life-threatening side effects, not all of which are disclosed on the drug’s safety label. Januvia pancreatic cancer lawsuit claims are now targeting Merck alleging its failure to warn the public, failure to adequately test its drug, and deliberate concealment of the risks.

Januvia And Pancreatic Cancer Side Effects Still Reported By Injured Patients

Written by on March 30, 2015

Despite numerous studies showing a potential link between Januvia and pancreatic cancer, the U.S. Food and Drug Administration has failed to uncover definitive evidence. That should not ease concerns about the drug’s impact on the pancreas. Several months after the FDA and European Medicines Agency (EMA) announced their findings, men and women continue to report incidents of cancer. Many of them have filed product liability lawsuits against the manufacturer.

Potential Complications Associated With Byetta And Thyroid Cancer Surgery

Written by on March 16, 2015

Side effects of Byetta, a medication prescribed to treat type 2 diabetes, may include an increased risk of thyroid cancer. That’s according to UCLA researchers who reviewed incidents of the disease found in the FDA’s Adverse Event Reporting System (FAERS). Their findings helped to spur a rash of Byetta cancer lawsuit claims against the manufacturer. Plaintiffs allege they developed cancerous tumors in their thyroid gland after taking the drug, a side effect the manufacturer failed to disclose.

Byetta And Thyroid Cancer: What To Expect During and After Thyroid Surgery

Written by on March 10, 2015

One of the most disturbing side effects potentially linked to the use of Byetta (trade name for the diabetes drug exenatide) is the onset of thyroid cancer. Former users have reported being diagnosed with cancerous tumors in their thyroid glands and surrounding lymph nodes. The connection between Byetta and thyroid cancer is more than coincidental. UCLA researchers found that individuals taking the medication may be 4.7 times as likely to develop the disease than individuals taking other diabetes drugs.

New Wrongful Death Januvia Lawsuit Links Diabetes Drugs And Pancreatic Cancer

Written by on February 16, 2015

Pharmaceutical giant Merck & Co. is no stranger to litigation over its prescription medications. Nor is it a stranger to offering massive settlements to injured plaintiffs. The drug currently gaining momentum in the U.S. federal court system is Januvia (sitagliptin). Merck obtained FDA approval in 2006 to market it as a treatment for type 2 diabetes. The company is now being sued by hundreds of individuals who allege Januvia caused them to develop pancreatic cancer.

Injured Plaintiffs Pursue Diabetes Drug Settlements Over Life-Threatening Pancreatic Cancer

Written by on February 10, 2015

Companies that manufacturer diabetes drugs like Byetta, Januvia, Janumet, Victoza and Onglyza are at the center of a fierce and growing controversy. Consumers have reported being diagnosed with pancreatic cancer after taking the medications. Hundreds of diabetes drug lawsuits have already been filed against the manufacturers on behalf of injured men and women. Many additional claims are expected to be filed in the near future.

Report Shows FDA’s System Failed To Consider Diabetes Drug Cancer Risk

Written by on February 2, 2015

A recent investigation into the U.S. Food and Drug Administration’s system for tracking adverse events linked to the use of diabetes drugs has uncovered alarming deficits. The system all but ensures that major incidents go unreported. Only a small percentage of cases potentially linking diabetes medications to cancer have been submitted to the FDA’s Adverse Event Reporting System (FAERS).

7 Reasons To File A Januvia Lawsuit for Pancreatic Cancer

Written by on January 9, 2015

Merck & Co., manufacturer of the blockbuster diabetes medication Januvia, has yet to admit its drug increases the risk of pancreatic cancer. But a growing number of former users are reporting being diagnosed with the disease. Merck is already facing hundreds of Januvia pancreatic cancer lawsuit claims in federal court, with many more cases expected to be filed in 2015.

Diabetes Drug Cancer Lawsuit: Class Action Versus Multidistrict Litigation (MDL)

Written by on December 26, 2014

The makers of several anti-diabetic medications are under fire after hundreds of reports of pancreatic cancer have surfaced among users. Products like Januvia, Janumet, Byetta, Bydureon, Onglyza and Tradjenta are suspected of causing cancerous tumors to grow in the pancreas. Hundreds of diabetes drug lawsuit claims are now pending against the manufacturers in state and federal district courts.

Studies Indicate Diabetes Drugs May Elevate The Risk Of Pancreatic Cancer

Written by on December 17, 2014

Diabetes medications like Byetta and Januvia have been taken by millions of people to help control their diabetes. But while the drugs are effective, taking them isn’t without risk. Several studies have demonstrated a possible connection between the popular diabetes drugs and pancreatic cancer. Now, thousands of patients have been diagnosed with pancreatic tumors and claim the manufacturers failed to warn them. They’re saddled with a disease that is accompanied by excruciating pain and usually ends in death. The companies behind the medications are now facing hundreds of diabetes drug lawsuit claims demanding compensation.

Merck Faces A Growing Number Of Januvia Lawsuit Settlement Claims For Pancreatic Cancer

Written by on November 13, 2014

In July 2013, the U.S. Food and Drug Administration announced that its investigation of a link between drugs like Januvia and pancreatic cancer had failed to produce evidence. The agency made clear that it would not force the manufacturers to revise their respective warning labels. Yet, thousands of individuals have complained that they were diagnosed with cancer in the pancreas after using such medications.

Diabetes Drug Lawsuit Attorneys: On Filing A Wrongful Death Lawsuit Claim For A Deceased Loved One

Written by on November 6, 2014

When a loved one dies from pancreatic cancer, his or her death creates a vacuum. Not only is the disease quick to advance through the body, but its development may seem entirely unfair to the decedent’s family members. They are left to try to make sense of it while grieving for their loss. The situation is even harder to deal with if the disease is caused by a pharmaceutical drug, particularly if the manufacturer failed to provide adequate warning to the victim. That describes the situation many people are now facing after their spouses and parents have died from complications caused by Januvia and pancreatic cancer.

Byetta Causing Pancreatic Cancer: Are The Concerns About Byetta And Pancreatic Cancer Overblown?

Written by on October 20, 2014

Recent research has pointed to an increased risk of pancreatic cancer with use of the diabetes medication exenatide (marketed as Byetta). Patients currently using the drug are understandably concerned. The manufacturer, Amylin Pharmaceuticals, has made no mention of the disease on the warning label. Unfortunately, symptoms associated with Byetta and pancreatic cancer can remain hidden until the disease starts to metastasize.

Januvia Lawsuit Settlement Claims Are Based On Scientific Evidence

Written by on September 10, 2014

A report published by the Institute for Safe Medication Practices (ISMP) highlighted a high incidence rate of serious pancreas-related injuries related to the use of medications prescribed to treat type 2 diabetes. Several studies have pointed to a possible link between Januvia and pancreatic cancer, leading many patients to file claims in hopes of a Januvia lawsuit settlement.

Januvia Pancreatic Cancer FAQ: Diabetic’s Guide To Issues Involving Januvia And Pancreatic Cancer Side Effects

Written by on September 4, 2014

Merck & Co. controls a large stable of commercially-successful pharmaceutical products. But its type 2 diabetes drug Januvia (sitagliptin) is its biggest moneymaker, generating in excess of $4 billion per year. But recent studies have provided a reminder that a drug’s commercial success has little to do with its safety. Scientists believe they have found a connection between Januvia and pancreatic cancer.

Why Hasn’t The FDA Addressed The Risk Of Byetta Pancreatic Cancer?

Written by on August 26, 2014

A growing number of diabetics who used Byetta have reportedly developed pancreatic cancer. Despite evidence showing a possible link between Byetta and pancreatic cancer, the FDA has chosen to allow it to remain on the market without any warning about the cancer. The watchdog agency has even been accused of protecting the manufacturer rather than focusing on the safety of the drug.

Januvia Pancreatic Cancer Studies: Medical Experts Debate The Risk Of Januvia Pancreatic Cancer

Written by on August 14, 2014

The diabetes drug Januvia has been one of Merck & Co.’s most reliable sources of profit for several years. Sitagliptin, in the form of Januvia and Janumet (sitagliptin and metformin), now generates more than $5 billion in annual sales. But reports of serious side effects have surfaced. Because of Merck’s alleged failure to adequately warn patients, it is now facing Januvia lawsuit claims.

Byetta and Pancreatic Cancer Frequently Asked Questions

Written by on August 7, 2014

Controversy continues to surround the anti-diabetes drug Byetta (exenatide) and its manufacturer Amylin Pharmaceuticals. Users of the medication are becoming increasingly aware that the warning label might not disclose all of the risks. Many are questioning whether the drug’s manufacturer has concealed a possible link to pancreatic cancer.

Doctors May Be In The Dark About Byetta Pancreatic Cancer Risk

Written by on July 30, 2014

There is growing concern that certain diabetes medications, such as Byetta, Januvia and Victoza, elevate the risk of life-threatening pancreatic side effects. Yet doctors continue to prescribe the treatments and often fail to test for pancreatic cancer tumors until it’s too late.

When To Hire A Diabetes Drug Lawsuit Attorney To Pursue Compensation

Written by on July 21, 2014

Diabetes drug lawsuit attorneys are reviewing thousands of claims for diabetics who used the drugs Januvia, Byetta or similar diabetes medications and suffered serious pancreas or thyroid-related injuries. Some patients have experienced acute pancreatitis, while others have been diagnosed with pancreatic cancer or thyroid cancer.

Januvia Side Effects Cancer Lawsuit: Did Merck Hide The Januvia Pancreatic Cancer Risk From The Public?

Written by on July 11, 2014

The Food and Drug Administration approved the diabetes medicine Januvia (sitagliptin) in 2006. The drug has since become one of Merck’s biggest sellers, generating in excess of $4 billion a year. But it has also become the subject of controversy. Concerns about a link between Januvia and pancreatic cancer have led to a rash of lawsuits filed against the manufacturer.

Tests Performed To Diagnose Januvia And Pancreatic Cancer Tumors

Written by on June 3, 2014

A study published in the medical journal Gastroenterology sparked controversy regarding whether Januvia and pancreatic cancer share a causal relationship. A second Januvia Cancer study in 2014 is also causing controversy following the report showing Januvia and Janumet had the highest disproportionality results for both pancreatitis and pancreatic cancer.

Januvia Cancer Side Effects Overview

Written by on May 27, 2014

Development of acute pancreatitis and an increased risk of pancreatic cancer have motivated many patients to look into filing Januvia cancer lawsuit claims against Merck & Co. Both disease outcomes were highlighted in a study published in the journal Gastroenterology.

Januvia Class Action Lawsuit vs. Incretin Mimetic MDL

Written by on May 7, 2014

While there is not currently a Januvia Class Action Lawsuit, individual lawsuits over Januvia and pancreatic cancer side effects were recently consolidated into a multidistrict litigation (MDL) in California. The MDL also includes cases filed on behalf of individuals who have been seriously harmed by other GLP-1-based drugs – namely Victoza, Byetta, and Janumet. The consolidation marks a step forward in the growing litigation against incretin mimetics.

Januvia Cancer Fears Have Minimal Effect on 2014 Revenues

Written by on April 29, 2014

Despite numerous reports of acute pancreatitis and growing concern about Januvia pancreatic cancer, profits from the type 2 diabetes drug continues to grow for Merck & Co. According to a Bloomberg news report on Merck’s first-quarter 2014 revenue, “In the U.S., Januvia sales benefited from price increases, as revenue from the drug grew 3 percent while prescriptions declined.”

Diabetes Drug Cancer Risk: New Study Shows Byetta/Januvia Have Elevated Associations in FDA Data

Written by on April 21, 2014

According to new research, GLP-1 agonists (Byetta, Bydureon and Victoza) and DPP-4 inhibitors (Januvia, Janumet, Onglyza, Nesina, Tradjenta and Jentadueto) continue to be associated with an elevated risk of pancreatitis and pancreatic cancer in the FDA’s Adverse Event Reporting System (FAERS). The report also indicated an increased risk of thyroid cancer in the GLP-1 class of diabetes drugs.

Januvia Lawsuit Deadline: How Much Time Do You Have To File A Januvia Cancer Lawsuit?

Written by on April 2, 2014

Individuals suffering from the side effects of Januvia and pancreatic cancer may be eligible to obtain a financial recovery from Merck, the drug’s manufacturer. But there is a limited time frame in which to file a claim. That time frame is known as the statute of limitations. It varies from state to state, and determines how much time you have to sue for compensation.

British Medical Journal Hints That Januvia Pancreatic Cancer Risk Has Been Downplayed

Written by on March 28, 2014

Merck’s phenomenally-successful anti-diabetic drug Januvia (trade name for sitagliptin) was introduced in the U.S. in 2006. Today, it generates in excess of $4 billion a year in sales. It has become the therapy of choice for countless diabetics with more than 50 million prescriptions dispensed worldwide. But new fears regarding a link between Januvia and pancreatic cancer have given many patients and physicians pause.

Three Studies in 2013 Fuel Fears Of Januvia Pancreatic Cancer Risk

Written by on March 20, 2014

Pharmaceutical companies are often at the center of controversy due to side effects caused by their products. The bigger the company, the more scrutiny it attracts. Thus, it shouldn’t come as a surprise that Merck & Co. is facing a growing number of Januvia lawsuit claims. The number is expected to continue rising as more patients learn the drug might cause pancreatic cancer.

Onglyza Side Effects Under Investigation by FDA

Written by on February 14, 2014

The FDA recently announced their intent to review heart failure risk with the diabetes drug saxagliptin, also known as Onglyza and Kombiglyze XR. The agency requested clinical trial data from the manufacturer following a study published in the New England Journal of Medicine, which reported an increased rate of hospitalization for heart failure with use of saxagliptin.

Early Detection Increases Chances of Whipple Procedure for Byetta, Victoza Pancreatic Cancer

Written by on February 3, 2014

The biotech industry is paying close attention to a pancreatic cancer test that Baltimore high school freshman Jack Andraka is currently developing. 60 Minutes recently reported on the young scientists’ journey from student to cancer researcher. “Jack’s test detects and unusually high level of mesothelin, a protein that the body produces in pancreatic cancer’s early — and most treatable — stage.”

Byetta Pancreatic Cancer Reports Prompt Changes in Lifestyle

Written by on January 27, 2014

Concern over reports of Bydureon and Byetta Pancreatic Cancer and Pancreatitis prompted blog-writer Ilene Raymond Rush to try something different. In October, 2013 the author began a new diet and exercise regimen and, after talking to her doctor, stopped taking Byetta and Bydureon. In her recent post, Life Without Byetta or Bydureon, she happily reports that here A1C levels are at 5.6 with a minor increase in her cholesterol levels.

New Medical Tests May Help Diagnose Januvia Pancreatic Cancer

Written by on January 13, 2014

News stories about medical tests for early detection of pancreatic cancer have been saturating the internet lately, as scientists and biologists from various research centers continue to search for ways to diagnose pancreatic cancer in it’s early stages. That’s great news for diabetes patients who may be concerned about developing Januvia Pancreatic Cancer side effects.

British Scientists May Have Found a New Treatment Option for Byetta Pancreatic Cancer

Written by on January 7, 2014

British Scientists from The University of Manchester published research results in The Journal of Biological Chemistry in December, 2013 for a new potential method of treating Byetta pancreatic cancer. Their strategy is based on selectively killing pancreatic cancer cells by cutting off the glycolysis energy source, causing a toxic calcium overload to the diseased cells.

Studies Indicate Potential Link Between Onglyza and Pancreatic Cancer, Pancreatitis

Written by on December 23, 2013

Onglyza (saxagliptin) is known as an “incretin mimetic” because it “mimics” an incretin hormone called GLP-1. It is given to type 2 diabetics, whose bodies don’t produce enough insulin or can’t respond to insulin effectively. The drug stimulates the pancreas to secrete insulin when meals are consumed, reducing the symptoms of diabetes. Unfortunately, questions have been raised about its safety. Researchers have repeatedly found evidence of a connection between incretin mimetics like Onglyza and pancreatic cancer.

Victoza Side Effects May Include Pancreatic Cancer

Written by on December 18, 2013

Victoza (liraglutide) is a diabetes drug belonging to a class of drugs called “incretin mimetics.” Approved in 2010, it has become popular for its ability to help diabetics manage their blood sugar and lose weight. Unfortunately, concerns about Victoza side effects have grown considerably in 2013, causing some patients to consider filing Victoza cancer lawsuits.

Plaintiffs to Present Evidence of Januvia Cancer Risk at Upcoming “Science Day” Hearings

Written by on December 16, 2013

Januvia Cancer Lawsuits alleging that diabetes drugs like Januvia, Janumet, Byetta, and Victoza are linked to pancreatic cancer have been progressing for months after being consolidated in a multi-district litigation. Now, there is another milestone on the horizon: the U.S. District Court of the Southern District of California, where the litigation is being heard, has scheduled science days for February 5-6, 2014.

California Woman Files Pancreatic Cancer Lawsuit Against Byetta and Januvia

Written by on December 11, 2013

This fall, a California widow filed a wrongful death lawsuit against the makers of diabetes medications Byetta & Januvia, claiming that her husband’s pancreatic cancer was caused by these drugs. Leeta Anderson’s lawsuit states that her husband began using Byetta and Januvia in September 2010, and died of cancer less than 2 years later. She believes that her husband’s diabetes medication, which they relied upon to keep him healthy, ultimately led to his cancer and death.

Byetta Side Effects: Cancer? Treatment Options for Byetta Users with Pancreatic Cancer

Written by on December 9, 2013

Although the diabetes drug Byetta (exenatide) was only approved in 2005, it has already gained a troubled reputation. On the one hand, many doctors and patients swear by its effectiveness. They say the medication helps to control blood sugar levels, a major benefit for diabetics. On the other hand, numerous reports have circulated about a possible connection between Byetta and pancreatic cancer. Former users claim that the drug caused them to develop malignant tumors in their pancreas.

Januvia Side Effects Lawsuits Allege Merck Hid Januvia Cancer Risk

Written by on December 5, 2013

Since its 2006 FDA approval, Januvia has since become one of Merck’s biggest sellers, generating in excess of $4 billion a year. But it has also become the subject of controversy. Concerns about a link between Januvia and pancreatic cancer have led to a rash of lawsuits filed against the manufacturer.

Scientist Seeks Possible Link Between Diabetes Drugs and Cancer

Written by on December 3, 2013

Dr. Peter Butler works as the Chief of Endocrinology, Diabetes, and Hypertension at the University of California Los Angeles. In this position, he has dedicated significant energy to investigating a potential link between diabetes drugs and cancer. Specifically, Butler’s research has focused on a class of drugs called “incretin mimetics” which includes common diabetes medications like Januvia, Byetta, Janumet, and Victoza. In 2009, Butler’s conducted one of his first investigations into the safety of these diabetes drugs: a study of the way diabetic rats were affected by the drug sitagliptin (Januvia).

Do Sitagliptin’s Side Effects Include Cancer?

Written by on November 28, 2013

Although sitagliptin has been proven effective at lowering blood sugar and treating type 2 diabetes, there are also a number of side effects. Some, like upset stomach, sore throat, upper respiratory infection, and headaches are relatively mild. Others, like kidney problems and pancreatitis, are significantly more serious. Perhaps most worrisome of all are recent concerns that one of sitagliptin’s side effects may be cancer.

FDA Investigating Januvia Pancreatic Cancer Risk

Written by on November 21, 2013

A recent announcement that the FDA will be reviewing Januvia’s pancreatic cancer risk, as well as ongoing research into this drug’s safety, has caused concern for numerous diabetics. Individuals who have taken this drug are now wondering if they will develop cancer, and what their next steps should be.

For Diabetics Taking Janumet, Cancer Becomes a Major Concern

Written by on November 19, 2013

In the past year, Janumet has lost some of its shine, its reputation tarnished by concerns that it may be linked to pancreatic cancer. Now, individuals who have taken Janumet are wondering whether this drug could have increased their risk of cancer, or even caused them to develop it.

The Science Behind Onglyza Lawsuit Claims

Written by on November 16, 2013

Concerns about the safety of certain diabetes medications have grown in recent months, even leading to lawsuits against the manufacturers of these drugs. One of the diabetes treatments at the center of this controversy is Onglyza, or saxagliptin, a member of the class of drugs known as incretin mimetics.

Is Januvia Causing Pancreatic Cancer?

Written by on November 13, 2013

So far this year, over 150 lawsuits have been filed against the makers of Januvia (sitagliptin) and two other diabetes drugs, Byetta and Victoza. Some have been filed by diabetics who have been diagnosed with pancreatic cancer, while many others have been filed by families who have lost a loved one to this disease. The plaintiffs involved come from numerous states, and have unique stories, but all share a common claim: that drugs like Januvia cause pancreatic cancer.

Are Concerns over Januvia’s Safety Causing Merck’s Stock Market Problems?

Written by on November 12, 2013

As research has identified numerous safety concerns associated with Januvia, including potential links to pancreatitis and pancreatic cancer, consumers have grown more wary about taking this medication. With many alternatives to Januvia and other incretin mimetic therapies available, some diabetics are determining that Januvia’s benefits are outweighed by a possible risk of pancreatic cancer. Now, this shift away from this diabetes drug may be causing financial problems for Januvia’s maker, Merck.

Pancreatic Cancer Lawsuits: Allegations Being Made Against the Drug Companies

Written by on November 6, 2013

When they first entered the prescription drug market, the class of diabetes medications known as incretin mimetics was hailed as a major breakthrough in type-2 diabetes research. These drugs have since made billions of dollars for the drug companies that produce them. Unfortunately, there are now growing fears that these drugs cause pancreatic cancer in some patients, leading some to file pancreatic cancer lawsuits.

Tradjenta and Pancreatic Cancer: How Pancreatic Cancer Attacks the Body

Written by on November 5, 2013

Scientific evidence suggests that there may be a relationship between the anti-diabetes drug Tradjenta and pancreatic cancer. The U.S. Food and Drug Administration is actively monitoring reports of pancreatitis and pancreatic cancer in individuals using certain diabetes drugs, including Tradjenta (linagliptin). Now, for many patients using Tradjenta, cancer is a serious concern.

Victoza Cancer Lawsuits Consolidated in California MDL

Written by on October 31, 2013

Victoza and pancreatic cancer lawsuits were recently consolidated into a multidistrict litigation (MDL) in California. The MDL also includes cases filed on behalf of individuals who have been seriously harmed by other GLP-1-based drugs – namely Januvia, Byetta, and Janumet. Although it may be some time before the first trials begin, the consolidation marks a step forward in the growing litigation against incretin mimetics.

Byetta and Pancreatic Cancer: How Great is the Risk?

Written by on October 29, 2013

Pancreatic cancer is an extremely dangerous disease with a very low survival rate: only about 6% of pancreatic cancer patients are still living 5 years after their first diagnosis. Recent research has indicated a possible link between the drug Byetta and pancreatic cancer, raising questions and concerns for diabetics using this drug to control their blood sugar.

Top Three Januvia Lawsuit Allegations Against Merck

Written by on October 24, 2013

When sitagliptin, sold as Januvia, was approved for sale by the FDA in 2006, diabetics were understandably excited. The oral medication developed by the pharmaceutical giant Merck & Co. was hailed as one of the most important diabetes advancements in years. At the time, few diabetics imagined that there might be a link between Januvia and pancreatic cancer. The lethal disease wasn’t listed on the drug’s label. However, seven years and more than 45 million prescriptions later, Merck is facing an increasing number of Januvia pancreatic cancer lawsuit claims.

Is Janumet included in the Januvia lawsuit?

Written by on October 22, 2013

In recent months, a great deal of publicity has been given to lawsuits being filed against the manufacturers of certain diabetes drugs. At the center of these claims is a relatively new class of drugs known as incretin mimetics—the medications in this class have been associated with a potential risk of pancreatic cancer. Much of the press given to these claims has focused on Byetta and Januvia lawsuits, since these are the most common medications in this class. This does not mean, however, that other incretin mimetic medications are excluded from legal proceedings. In addition to claims against the makers of Januvia and Byetta, Janumet lawsuits are currently being filed by our legal team.

Januvia Pancreatic Cancer Risk: Should the FDA Recall Januvia?

Written by on October 20, 2013

Dozens of lawsuits contending that there is a serious pancreatic cancer risk associated with Januvia and other incretin mimetics were filed in the summer of 2013. Additionally, the FDA has received hundreds of reports of pancreatitis in patients taking these medications. This news has left diabetics taking Januvia wondering: What is the Januvia-pancreatic cancer risk?

Pancreatic Cancer Survival Rates: Exocrine vs. Endocrine Tumors

Written by on October 17, 2013

Pancreatic cancer is, sadly, notorious for having a very low survival rate. While research into other types of cancer, like prostate or breast cancer, has successfully lowered their mortality rate, the prognosis for pancreatic cancer remains stubbornly poor. Among all individuals diagnosed with pancreatic cancer, the five-year survival rate is only 3%, a statistic that has not changed significantly in the last 40 years.

Why Hasn’t There Been an FDA Recall on Diabetes Drugs?

Written by on October 10, 2013

After the publication of recent research, a growing number of individuals are calling for diabetes drugs known as incretin mimetics to be withdrawn from the market. They claim these drugs presents too high a risk to public safety to warrant their widespread availability. The main concern is a potential relationship between Januvia and pancreatic cancer. Many fear that using medication significantly increases the risk of developing the disease.

What To Do if You Think Byetta Caused the Death of a Family Member

Written by on October 8, 2013

Pancreatic cancer is a deadly disease that is often diagnosed late in its course. For family members, its progression can be shocking—the health of their loved one can decline in matter of weeks or months. After the death of a relative there may be questions: Did Byetta cause this cancer? Could it have been found sooner? Was it preventable?

Is there a Januvia Class Action Lawsuit?

Written by on October 3, 2013

As the number of individuals filing claims against the manufacturer of Januvia continues to grow, many people are wondering if these claims will be consolidated into a Januvia class action lawsuit in which all Januvia claims are combined into a single lawsuit. In fact, despite the rapidly increasing size of this case area, it is unlikely that there will ever be a Januvia class action. Instead, claims are being filed against the manufacturer of Januvia on an individual basis.

Janumet and Pancreatic Cancer Risk

Written by on October 1, 2013

Concerns about Janumet and pancreatic cancer were heightened recently, when a recent study published in the journal Gastroenterology identified a potential link between Janumet and cancer. Led by Dr. Peter Butler of UCLA, the study’s authors concentrated on the effects of using certain diabetes medications.

Byetta Side Effects: a Timeline Leading to Fears about Byetta and Pancreatic Cancer

Written by on September 27, 2013

A potential connection between Byetta and pancreatic cancer is only the most recent in a string of concerns surrounding the safety of the diabetes medication. Also known by its generic name exenatide, the drug was approved for sale in the U.S. in 2005. In the years since, there have been numerous reports of serious side effects linked to this medication. The first Byetta lawsuit claim was filed in 2008, paving the way for additional cases.

Lawsuits Filed Against Victoza Manufacturer Allege Pancreatic Cancer Link

Written by on September 25, 2013

The anti-diabetic drug Victoza has become the focus of intense scrutiny during the last few years as the public becomes aware of a possible link between this medication and cancer. Consumers and physicians are concerned about Victoza’s adverse effects. Some users have already been diagnosed with pancreatic cancer, a disease accompanied by a poor prognosis. Now, individuals are filing lawsuits against Victoza’s manufacturer, alleging the company never informed them about the risk.

Byetta and Thyroid Cancer Are Linked, Plaintiffs Allege

Written by on August 26, 2013

The FDA requires that diabetes medications Bydureon (exenatide) and Victoza (liraglutide) display black box packaging warnings about a potential risk of thyroid cancer based on animal studies that identified thyroid tumors in rodents given these drugs. Even though it contains the same generic medication as Bydureon, there is currently no warning about Byetta and thyroid cancer.

Did Byetta’s Maker Know the Risks?

Written by on August 15, 2013

On June 10, 2013, the British Medical Journal published a feature report that investigated whether the potential pancreatic harm caused by diabetes drugs like Byetta had been underplayed. One of the particularly troubling aspects of this article was the revelation that drug companies may have had early warning signs of a risk, and then downplayed that risk.

Januvia Pancreatitis: The FDA’s New Safety Information

Written by on August 13, 2013

In 2009, the FDA released a safety alert announcing changes in the prescribing information for Januvia and Janumet.  The labels of these medications now warn that patients who take them may be at an increased risk of developing acute pancreatitis, a serious and painful condition that requires immediate medical attention.

Resources for Those Affected by Pancreatic Cancer

Written by on August 2, 2013

A pancreatic cancer diagnosis can leave patients and families feeling alone and isolated, unsure of where to turn next. Find a number of pancreatic cancer charities and resources that offer support to those affected by this devastating disease.

British Medical Journal Questions Diabetes Drug Safety

Written by on June 12, 2013

A June 10th, 2013 article in British newspaper the Yorkshire Post reported mounting concern in the international medical community over the possible dangers of certain diabetes drugs. Increasingly, the class of medications known as incretin mimetics has come under scrutiny as researchers link these drugs to increased incidences of pancreatitis and pancreatic cancer. This class of medications includes the popular drug Victoza, produced by the Danish pharmaceutical company Novo Nordisk, as well as Onglyza, Nesina, Tradjenta, Januvia, and Byetta.

Is Cancer a Side Effect of Onglyza?

Written by on June 12, 2013

The diabetes drug Onglyza has been drawing scrutiny from researchers and diabetes patients in 2013 as research that may link it to pancreatic cancer comes to light.  Although this drug has been proven effective in treating diabetes, its costs may outweigh its benefits for patients who develop serious pancreatic side effects.

Is Victoza Safe to Use?

Written by on June 12, 2013

The diabetes drug Victoza, or liraglutide, has become increasingly controversial as medical professionals continue to question its safety. The drug already carries a “black box warning,” a warning that appears on the labels of medications that have serious or life-threatening side effect risks. Now, a public safety watchdog group called Public Citizen is calling for it to be removed from the market due to dangerous cancer side effects.

ISMP Warns About Diabetes Drugs

Written by on June 12, 2013

The Institute for Safe Medication Practices, or ISMP, a nonprofit patient safety organization dedicated to safe medication use, issued a MedWatch report in April 2013 that investigated the safety of a widely prescribed class of diabetes medications called incretin mimetics.  Among the medications scrutinized in the report were Victoza (liraglutide), Onglyza (saxagliptin), and Tradjenta (lingaliptin).

2013 Diabetes Drug Cancer News

Written by on June 12, 2013

The class of diabetes drugs known as incretin mimetics have been widely prescribed since being approved by the FDA. Although popular for the treatment of diabetes, there is increasing concern in the medical community that these drugs may be linked to pancreatic cancer.

Byetta Side Effects

Written by on May 15, 2013

Byetta (exenatide) has recently come under scrutiny due to a potential elevated risk of pancreatic cancer as a side effect of Byetta. This medication is manufactured by Amylin Pharmaceuticals, Inc. and was first approved by the FDA in 2005 for the treatment of Type-2 diabetes. Byetta is an injectable drug that increases insulin production by enhancing the actions of a gut hormone called glucagon-like peptide (GLP-1). Exenatide mimics the action of GLP-1, a compound manufactured in the body that regulates insulin production.

Januvia Side Effects

Written by on May 13, 2013

Januvia (sitagliptin) has recently come under scrutiny due to a potential elevated risk of cancer as a side effect of Januvia. This medication is manufactured by Merck & Co., Inc. and was first approved by the FDA in 2006 for the treatment of Type-2 diabetes. Januvia is an oral medication that slows down the breakdown of incretin hormones, which in turn increases insulin production. Sitagliptin mimics the action of GLP-1, an incretin that stimulates insulin production.

Nationwide Claims Help

Click on your state for more information or call 1-888-578-4754.

AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC